In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

References

1. Hubka V, Mencl K, Skorepova M, Lyskova P, Zalabska E. Phaeohyphomycosis and onychomycosis due to Chaetomium spp., including the first report of Chaetomium brasiliense infection. Med Mycol 2011; 49:724–733 [View Article]
   [Google Scholar]
2. Aspiroz C, Gené J, Rezusta A, Charlez L, Summerbell RC. First Spanish case of onychomycosis caused by Chaetomium globosum . Med Mycol 2007; 45:279–282 [View Article]
   [Google Scholar]
3. Serena C, Ortoneda M, Capilla J, Pastor FJ, Sutton DA et al. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother 2003; 47:3161–3164 [View Article]
   [Google Scholar]
4. Wang H, Liu Y, Chen SC, Long Y, Kong F et al. Chaetomium atrobrunneum and Aspergillus fumigatus in multiple tracheal aspirates: copathogens or symbiosis. J Microbiol Immunol Infect 2016; 49:281–285 [View Article]
   [Google Scholar]
5. Barron MA, Sutton DA, Veve R, Guarro J, Rinaldi M et al. Invasive mycotic infections caused by Chaetomium perlucidum, a new agent of cerebral phaeohyphomycosis. J Clin Microbiol 2003; 41:5302–5307 [View Article]
   [Google Scholar]
6. Guppy KH, Thomas C, Thomas K, Anderson D. Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen-Chaetomium atrobrunneum: case report. Neurosurgery 1999; 45:200
   [Google Scholar]
7. Hattori N, Adachi M, Kaneko T, Shimozuma M, Ichinohe M et al. Case report. Onychomycosis due to Chaetomium globosum successfully treated with itraconazole. Mycoses 2000; 43:89–92 [View Article]
   [Google Scholar]
8. Shi D, Lu G, Mei H, de Hoog GS, Zheng H et al. Onychomycosis due to Chaetomium globosum with yellowish black discoloration and periungual inflammation. Med Mycol Case Rep 2016; 13:12–16 [View Article]
   [Google Scholar]
9. Kim DM, Lee MH, Suh MK, Ha GY, Kim H et al. Onychomycosis caused by Chaetomium globosum . Ann Dermatol 2013; 25:232–236 [View Article]
   [Google Scholar]
10. Lagacé J, Cellier E. A case report of a mixed Chaetomium globosum/Trichophyton mentagrophytes onychomycosis. Med Mycol Case Rep 2012; 1:76–78 [View Article]
    [Google Scholar]
11. Yu J, Yang S, Zhao Y, Li R. A case of subcutaneous phaeohyphomycosis caused by Chaetomium globosum and the sequences analysis of C. globosum . Med Mycol 2006; 44:541–545 [View Article]
    [Google Scholar]
12. Guarro J, Soler L, Rinaldi MG. Pathogenicity and antifungal susceptibility of Chaetomium species. Eur J Clin Microbiol Infect Dis 1995; 14:613–618 [View Article]
    [Google Scholar]
13. Pujol I, Guarro J, Llop C, Soler L, Fernández-Ballart J. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob Agents Chemother 1996; 40:2106–2110 [View Article]
    [Google Scholar]
14. Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris . Antimicrob Agents Chemother 2017; 61: [View Article]
    [Google Scholar]
15. Al-Sweih N, Ahmad S, Joseph L, Khan S, Vayalil S et al. Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin. J Clin Microbiol 2015; 53:1038–1041 [View Article]
    [Google Scholar]
16. Denardi LB, Oliveira V, de Jesus FPK, Dalla-Lana BH, Santurio JM et al. In vitro interactions of azoles and echinocandins against clinical strains of Aspergillus flavus . Med Mycol 2018; 56:1006–1011 [View Article]
    [Google Scholar]
17. Uemura S, Tamura A, Yamamoto N, Saito A, Nakamura S et al. Successful combination therapy of liposomal amphotericin B and caspofungin for disseminated fusariosis in a pediatric patient with acute lymphoblastic leukemia. Pediatr Infect Dis J 2018; 37:e251–e253 [View Article]
    [Google Scholar]
18. Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opin Pharmacother 2009; 10:2723–2733 [View Article]
    [Google Scholar]
19. Zhang S, Li R, Yu J. Drug combinations against Mucor irregularis in vitro . Antimicrob Agents Chemother 2013; 57:3395–3397 [View Article]
    [Google Scholar]
20. Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, approved standard—2nd ed: M38–A2. Clinical and Laboratory Standards Institute. Wayne, PA: 2008
    [Google Scholar]
21. Vitale RG, Afeltra J, Dannaoui E. Antifungal combinations. Methods Mol Med 2005; 118:143–152
    [Google Scholar]
22. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011; 86:805–817 [View Article]
    [Google Scholar]
23. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001; 10:269–280 [View Article]
    [Google Scholar]
24. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus . J Antimicrob Chemother 2003; 51:1423–1425 [View Article]
    [Google Scholar]
25. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46:3039–3041 [View Article]
    [Google Scholar]
26. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53:2382–2391 [View Article]
    [Google Scholar]
27. Lockhart SR, Ghannoum MA, Alexander BD. Establishment and use of epidemiological cutoff values for molds and yeasts by use of the clinical and laboratory Standards Institute M57 standard. J Clin Microbiol 2017; 55:1262–1268 [View Article]
    [Google Scholar]
28. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro—in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24:235–247 [View Article]
    [Google Scholar]